News | June 08, 2024
Lupin completes acquisition of two brands from Sanofi in Europe and Canada
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
